Shares of Abbott Laboratories plunged 10.04% to $108.61 Thursday, on what proved to be an all-around great trading session ...

Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making its stock look attractively valued. The move, driven ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...

Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, ...

Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table encapsulates their recent ratings, offering a ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be reporting earnings this Thursday before market open. Here’s what to look for.

This was the stock's fourth consecutive day of losses.

This was the stock's second consecutive day of losses.